AACR 2022 | Are combination approaches the way forward for treating patients with triple-negative breast cancer?

Sangeetha M. Reddy, MD, UT Southwestern Medical Center, Dallas, TX, explains that some patients with triple-negative breast cancer (TNBC) respond to single-agent immunotherapy, so we need to find ways to select these patients in advance to avoid subjecting them to unnecessary toxicities. However, we have seen the most success when using combination approaches, as immunotherapy is accessible to most patients through combinations with chemotherapy. Further research is required to uncover novel immunotherapy combinations and systematically identify and target deficiencies in the anti-tumor immune response. This interview took place at the American Association for Cancer Research Annual Meeting in New Orleans, LA.